AnalystsCharles DuncanCharles Duncan's Stock Forecasts
AnalystsCharles Duncan
Ranking
Top 1%
#24 out of 3510 analysts
Average Return
+102.96%
Win Rate
51%21 out of 41
Risk vs Reward
Poor
Good
Charles Duncan's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Novavax IncNVAX | +2,273.26% | $9.50 | $225.46 | 2020-03-17 - 2021-03-17 | Strong Buy |
Cassava Sciences IncSAVA | +1,268.03% | $9.32 | $127.50 | 2020-10-23 - 2021-07-27 | Strong Buy |
Aimmune Therapeutics IncAIMT | +175.26% | $12.53 | $34.49 | 2020-03-23 - 2020-10-12 | Strong Buy |
Novavax IncNVAX | +169.36% | $64.75 | $174.41 | 2020-06-19 - 2021-06-18 | Strong Buy |
Prevail Therapeutics IncPRVL | +103.54% | $11.30 | $23.00 | 2020-09-11 - 2021-01-21 | Strong Buy |
Charles Duncan's Stock Coverage
| Name / Ticker | # of Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
ATAI Life Sciences NVATAI | 1 | Strong Buy | $45.00 | -63.80% | Initiates Coverage On | 19 days ago |
Novavax IncNVAX | 5 | Strong Buy | $272.00 | -34.19% | Maintains | 2 months ago |
Biohaven Pharmaceutical Holding Co LtdBHVN | 3 | Strong Buy | $140.00 | -11.74% | Maintains | 2 months ago |
Clene IncCLNN | 1 | Strong Buy | $22.00 | -64.55% | Initiates Coverage On | 3 months ago |
Ovid Therapeutics IncOVID | 1 | Hold | $4.00 | -6.75% | Downgrades | 3 months ago |
Lumos Pharma IncLUMO | 1 | Strong Buy | $32.00 | -76.28% | Initiates Coverage On | 8 months ago |
Cassava Sciences IncSAVA | 1 | Strong Buy | $24.00 | +431.25% | Initiates Coverage On | 9 months ago |
Inovio Pharmaceuticals IncINO | 5 | Hold | $12.00 | -31.17% | Downgrades | 10 months ago |
Prevail Therapeutics IncPRVL | 1 | Strong Buy | $26.00 | -11.54% | Initiates Coverage On | a year ago |
Fennec Pharmaceuticals IncFENC | 1 | Strong Buy | $18.00 | N/A | Initiates Coverage On | a year ago |
Geron CorpGERN | 1 | Strong Buy | $4.00 | N/A | Maintains | a year ago |
Halozyme Therapeutics IncHALO | 2 | Strong Buy | $39.00 | N/A | Reiterates | a year ago |
Axsome Therapeutics IncAXSM | 3 | Strong Buy | $131.00 | N/A | Maintains | a year ago |
Cara Therapeutics IncCARA | 1 | Strong Buy | $34.00 | N/A | Reiterates | a year ago |
Cytokinetics IncCYTK | 1 | Strong Buy | $23.00 | N/A | Reiterates | a year ago |
Aimmune Therapeutics IncAIMT | 2 | Strong Buy | $32.00 | N/A | Maintains | a year ago |
Acadia Pharmaceuticals IncACAD | 4 | Strong Buy | $75.00 | N/A | Reiterates | a year ago |
Reata Pharmaceuticals IncRETA | 2 | Strong Buy | $320.00 | N/A | Reiterates | a year ago |
Intra-Cellular Therapies IncITCI | 3 | Strong Buy | $47.00 | N/A | Reiterates | a year ago |
Catalyst Pharmaceuticals IncCPRX | 1 | Strong Buy | $12.00 | N/A | Reiterates | a year ago |
Adamas Pharmaceuticals IncADMS | 1 | Hold | $7.00 | N/A | Reiterates | 2 years ago |
Corcept Therapeutics IncCORT | 3 | Hold | $14.00 | N/A | Downgrades | 3 years ago |
Vanda Pharmaceuticals IncVNDA | 1 | Hold | $26.00 | N/A | Initiates Coverage On | 3 years ago |
Acorda Therapeutics IncACOR | 1 | Hold | $32.00 | N/A | Initiates Coverage On | 3 years ago |
vTv Therapeutics IncVTVT | 1 | Hold | N/A | N/A | Downgrades | 3 years ago |
Sangamo Therapeutics IncSGMO | 1 | Strong Buy | N/A | N/A | Upgrades | 4 years ago |
Altimmune IncALT | 1 | Strong Buy | $6.00 | N/A | Initiates Coverage On | 4 years ago |
Zynerba Pharmaceuticals IncZYNE | 1 | Strong Buy | N/A | N/A | Upgrades | 4 years ago |
Pdl Biopharma IncPDLI | 1 | Strong Buy | $4.00 | N/A | Reinstates | 5 years ago |
©2021 WallStreetZen
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.